Digital Biomarkers Market Overview

The Global Digital Biomarkers Market size is expected to grow from USD 3.56 billion in 2023 to USD 75.61 billion by 2032, at a CAGR of 40.43% during the forecast period (2024-2032)

The digital biomarkers industry represents a cutting-edge intersection of healthcare, technology, and data analytics, poised to revolutionize how we monitor and manage health conditions. Unlike traditional biomarkers, which are measurable indicators of biological processes or conditions, digital biomarkers are derived from data collected through digital devices such as smartphones, wearables, or sensors. This data includes physiological measurements, movement patterns, sleep quality, and even speech patterns, all of which can provide valuable insights into an individual's health status.

Digital biomarkers have a significant benefit in their capacity to collect data constantly in real-time, providing a more thorough and dynamic understanding of an individual's health in contrast to occasional clinic appointments or conventional testing procedures. This ongoing observation can facilitate timely identification of health problems, individualized treatments, and more accurate control of chronic conditions. Additionally, digital biomarkers make it easier to monitor patients remotely, which is becoming more important in a healthcare system that is shifting towards decentralized care and telemedicine.

Advancements in sensor technology, artificial intelligence, and data analytics are driving the growth of the digital biomarkers industry by enabling the interpretation and application of large amounts of health-related data. Businesses and research facilities are currently engaged in the creation and verification of fresh digital indicators in various areas such as heart disease, diabetes, mental health ailments, and neurological disorders. Regulatory bodies are also starting to create systems for verifying and authorizing digital biomarkers, enabling their incorporation into healthcare systems and clinical practice globally.

Market Dynamics And Factors Of Digital Biomarkers Market

Drivers:

Need For Improved Diagnostics And Integration of Digital Devices To Monitor Health Propelling The Market

Companion diagnostics and biomarkers have become increasingly relevant in the practice of medicine, leading to improved diagnosis, treatment, and monitoring across several disease areas. It can be used to identify patients likely to respond well to certain drugs or treatment options. These diagnostics are often used in conjunction with a specific drug. For instance, the Oncomine Dx Target Test (Thermo Fisher Scientific, Inc.) helps in biomarker testing of non-small cell lung cancer (NSCLC) patients eligible for ROZLYTREK (entrectinib). The expansion of the digital biomarkers market can be attributed to an increase in the usage of connected digital devices and health-related mobile applications. These devices aid in a range of diagnostic and prognostic measurements over diverse disease areas including mental health, diabetes, neurological diseases, and cardiovascular diseases. Rising usage of smartphones and the emergence of smartwatches, which aid in tracking the physiological details of the person's health, boost the digital biomarkers market. Technological advances in the range of mobiles and digitally connected technologies further propel the digital biomarkers market. Significant product launches and approvals from the FDA also drive the digital biomarkers market. For instance, in April 2020, the U.S. FDA approved KardiaMobile, by AliveCor, an AI-enabled wearable device that is designed to monitor a person's vital signs. It helps detect three highly common forms of heart arrhythmias.

Restraints:

Stringent Regulations And Affordability Impede The Growth Of The Market

There are barriers to broad acceptance, as there are with any emergent technology. Not all health information can be found, collected, or used. Many digital biomarker therapies are still experimental rather than common. Clinical procedures, legacy systems, workplace culture, and EU and international legislation can all make new digital biomarker technology adoption and integration challenges. Furthermore, pricey and intrusive digital biomarker therapies hinder wider adoption and are often ineffective since they lengthen a patient's stay in the hospital rather than at home.

Opportunities:

Voice Based Digital Biomarker Presents Substantial Growth Opportunity

Voice-based digital biomarkers are a forerunner of a biological research and healthcare revolution to come. The quality of a patient's voice is both a clear indicator of their health and a new frontier in health evaluation. Technologies that allow for speech capture on daily consumer devices and then do symptom recognition and prediction have enormous promise in both research and clinical practice. However, because these biomarkers are so new, there are significant uncertainties regarding how to bring them to market and use them effectively. Analytical validation entails verifying the quality and consistency of data processing and computed measures, as well as determining test-retest reliability, demographic variability, and comparing measurements to reference standards. Clinical validity is the process of ensuring that a measure corresponds to clinical outcomes such as diagnosis, illness progression, and therapy response. We give guidelines for the sorts of an evaluation required for speech-based biomarkers in each of these areas, as well as examine published examples. The examples in this study are specific to speech-based biomarkers, but they may be utilized as a model for developing digital biomarkers in general. One of the primary facilitators of voice-based digital biomarkers is EVOCAL Health GmbH.

Segmentation Analysis Of Digital Biomarkers Market

By System Component, Data collection tools dominate the digital biomarkers market. The cheap cost and greater scalability of digital biomarkers based on smartphone applications make it possible to access previously unavailable social, behavioral, psychological, and environmental data. Due to its capacity to evaluate health status, the development and progression of illnesses, and health conditioning monitoring using a non-invasive technique in healthcare research, biosensors had a substantial digital biomarker market share in 2020.

By Therapeutic Area, Cardiovascular Disease accounted for the largest share of digital biomarkers in the market. In cardiovascular disorders, digital biomarkers provide greater in-depth insights into the heart response of individuals during standardized exercise. The data generated by digital biomarkers have the potential to improve cardiac rehabilitation outcomes by optimizing and improving patient-centric treatment techniques.

By End User, Biopharmaceutical dominates the Digital Biomarkers Market.  Digital biomarkers are thought to be most useful in the early stages of drug research when pharmaceutical experts need to know if the medicine is successful or not before moving on to a phase III study and validating the results. For example, in the case of Alzheimer's and Parkinson's illnesses, the effectiveness of the treatments cannot be confirmed until the phase III trial, which has resulted in high-profile, cost-prohibitive failures that have cost pharmaceutical companies millions of dollars in the drug development process.

Regional Analysis Of Digital Biomarkers Market

North America remains a frontrunner in the digital biomarkers market, driven by robust investments in healthcare technology and a supportive regulatory environment. The region is home to numerous pioneering companies and research institutions advancing digital biomarker development. Dominance in North America is bolstered by strong collaborations between technology firms, healthcare providers, and academic centers, fostering innovation and commercialization. The United States, in particular, leads in regulatory advancements, with the FDA increasingly engaging in discussions and guidelines for digital biomarker validation and integration into clinical practice.

Europe boasts a robust digital biomarkers landscape, led by countries like Germany, the UK, and France, which serve as key hubs for innovation and research in digital health. The region benefits from a diverse regulatory environment under the European Union, with bodies like the EMA actively paving the way for digital biomarker adoption. Meanwhile, Asia-Pacific is experiencing rapid growth driven by technological advancements and increased healthcare investments in nations such as China, Japan, and South Korea. Despite varying regulatory frameworks, the region's proactive stance on digital healthcare transformation fuels demand for solutions like digital biomarkers, addressing pressing healthcare needs like aging populations and chronic diseases.

The digital biomarkers industry is witnessing global expansion driven by technological innovation, regulatory advancements, and increasing healthcare needs. While North America and Europe lead in terms of market dominance and regulatory maturity, Asia-Pacific and emerging markets offer significant growth opportunities fueled by technological adoption and evolving healthcare landscapes.

Top Key Players Covered In Digital Biomarkers Market

• AliveCor Inc.
• Bayer AG
• Evidation Health Inc.
• Fitbit Inc.
• Happify Health
• Koninklijke Philips NV
• Neurotrack Technologies Inc.
• GlaxoSmithKline Inc.
• Novartis International AG
• F. Hoffmann-La Roche Ltd.

Key Industry Developments in Digital Biomarkers Market

• In March 2024, Koneksa announced Merck's participation in its Data Syndication Partnership program for the LEARNS observational study on Parkinson’s digital biomarkers. Merck, joining as a member, gained real-time access to study data from smartphone-based and wearable technology assessments. The collaboration aimed to advance digital measures for Parkinson’s disease progression and treatment assessment through innovative data-sharing initiatives.
• In February 2024, Biofourmis secured four new agreements with top-20 pharmaceutical firms, driven by its expertise in digital biomarker development and decentralized clinical trial solutions. These partnerships focused on advancing oncology therapies through cutting-edge data science and technology, enhancing remote patient monitoring and safety measures. The agreements expand Biofourmis' global clinical trial footprint, spanning key regions including the United States, Europe, Asia-Pacific, and the Middle East, reflecting a strategic alignment with industry trends towards digital endpoints in drug development.

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By System Component
 3.2 By Therapeutic Area
 3.3 By End User

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  3.5.1 Drivers
  3.5.2 Restraints
  3.5.3 Opportunities
  3.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 4: Digital Biomarkers Market by System Component
 4.1 Digital Biomarkers Market Overview Snapshot and Growth Engine
 4.2 Digital Biomarkers Market Overview
 4.3 Data Collection Tools
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Data Collection Tools: Grographic Segmentation
 4.4 Data Integration Systems
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Data Integration Systems: Grographic Segmentation

Chapter 5: Digital Biomarkers Market by Therapeutic Area
 5.1 Digital Biomarkers Market Overview Snapshot and Growth Engine
 5.2 Digital Biomarkers Market Overview
 5.3 Cardiovascular Disease
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Cardiovascular Disease: Grographic Segmentation
 5.4 Sleep and Movement Disease
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Sleep and Movement Disease: Grographic Segmentation
 5.5 Neurodegenerative Disorders
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size (2017-2032F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Neurodegenerative Disorders: Grographic Segmentation
 5.6 Psychiatric Disorder
  5.6.1 Introduction and Market Overview
  5.6.2 Historic and Forecasted Market Size (2017-2032F)
  5.6.3 Key Market Trends, Growth Factors and Opportunities
  5.6.4 Psychiatric Disorder: Grographic Segmentation
 5.7 Gastrointestinal Disease
  5.7.1 Introduction and Market Overview
  5.7.2 Historic and Forecasted Market Size (2017-2032F)
  5.7.3 Key Market Trends, Growth Factors and Opportunities
  5.7.4 Gastrointestinal Disease: Grographic Segmentation
 5.8 Respiratory Disease
  5.8.1 Introduction and Market Overview
  5.8.2 Historic and Forecasted Market Size (2017-2032F)
  5.8.3 Key Market Trends, Growth Factors and Opportunities
  5.8.4 Respiratory Disease: Grographic Segmentation
 5.9 Diabetes
  5.9.1 Introduction and Market Overview
  5.9.2 Historic and Forecasted Market Size (2017-2032F)
  5.9.3 Key Market Trends, Growth Factors and Opportunities
  5.9.4 Diabetes: Grographic Segmentation
 5.10 Others
  5.10.1 Introduction and Market Overview
  5.10.2 Historic and Forecasted Market Size (2017-2032F)
  5.10.3 Key Market Trends, Growth Factors and Opportunities
  5.10.4 Others: Grographic Segmentation

Chapter 6: Digital Biomarkers Market by End User
 6.1 Digital Biomarkers Market Overview Snapshot and Growth Engine
 6.2 Digital Biomarkers Market Overview
 6.3 Biopharmaceutical
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Biopharmaceutical: Grographic Segmentation
 6.4 Providers
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Providers: Grographic Segmentation
 6.5 Payers
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size (2017-2032F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Payers: Grographic Segmentation

Chapter 7: Company Profiles and Competitive Analysis
 7.1 Competitive Landscape
  7.1.1 Competitive Positioning
  7.1.2 Digital Biomarkers Sales and Market Share By Players
  7.1.3 Industry BCG Matrix
  7.1.4 Ansoff Matrix
  7.1.5 Digital Biomarkers Industry Concentration Ratio (CR5 and HHI)
  7.1.6 Top 5 Digital Biomarkers Players Market Share
  7.1.7 Mergers and Acquisitions
  7.1.8 Business Strategies By Top Players
 7.2 ALIVECOR INC.
  7.2.1 Company Overview
  7.2.2 Key Executives
  7.2.3 Company Snapshot
  7.2.4 Operating Business Segments
  7.2.5 Product Portfolio
  7.2.6 Business Performance
  7.2.7 Key Strategic Moves and Recent Developments
  7.2.8 SWOT Analysis
 7.3 BAYER AG
 7.4 EVIDATION HEALTH INC.
 7.5 FITBIT INC.
 7.6 HAPPIFY HEALTH
 7.7 KONINKLIJKE PHILIPS NV
 7.8 NEUROTRACK TECHNOLOGIES INC.
 7.9 GLAXOSMITHKLINE INC.
 7.10 NOVARTIS INTERNATIONAL AG
 7.11 F. HOFFMANN-LA ROCHE LTD.

Chapter 8: Global Digital Biomarkers Market Analysis, Insights and Forecast, 2017-2032
 8.1 Market Overview
 8.2 Historic and Forecasted Market Size By System Component
  8.2.1 Data Collection Tools
  8.2.2 Data Integration Systems
 8.3 Historic and Forecasted Market Size By Therapeutic Area
  8.3.1 Cardiovascular Disease
  8.3.2 Sleep and Movement Disease
  8.3.3 Neurodegenerative Disorders
  8.3.4 Psychiatric Disorder
  8.3.5 Gastrointestinal Disease
  8.3.6 Respiratory Disease
  8.3.7 Diabetes
  8.3.8 Others
 8.4 Historic and Forecasted Market Size By End User
  8.4.1 Biopharmaceutical
  8.4.2 Providers
  8.4.3 Payers

Chapter 9: North America Digital Biomarkers Market Analysis, Insights and Forecast, 2017-2032
 9.1 Key Market Trends, Growth Factors and Opportunities
 9.2 Impact of Covid-19
 9.3 Key Players
 9.4 Key Market Trends, Growth Factors and Opportunities
 9.4 Historic and Forecasted Market Size By System Component
  9.4.1 Data Collection Tools
  9.4.2 Data Integration Systems
 9.5 Historic and Forecasted Market Size By Therapeutic Area
  9.5.1 Cardiovascular Disease
  9.5.2 Sleep and Movement Disease
  9.5.3 Neurodegenerative Disorders
  9.5.4 Psychiatric Disorder
  9.5.5 Gastrointestinal Disease
  9.5.6 Respiratory Disease
  9.5.7 Diabetes
  9.5.8 Others
 9.6 Historic and Forecasted Market Size By End User
  9.6.1 Biopharmaceutical
  9.6.2 Providers
  9.6.3 Payers
 9.7 Historic and Forecast Market Size by Country
  9.7.1 U.S.
  9.7.2 Canada
  9.7.3 Mexico

Chapter 10: Europe Digital Biomarkers Market Analysis, Insights and Forecast, 2017-2032
 10.1 Key Market Trends, Growth Factors and Opportunities
 10.2 Impact of Covid-19
 10.3 Key Players
 10.4 Key Market Trends, Growth Factors and Opportunities
 10.4 Historic and Forecasted Market Size By System Component
  10.4.1 Data Collection Tools
  10.4.2 Data Integration Systems
 10.5 Historic and Forecasted Market Size By Therapeutic Area
  10.5.1 Cardiovascular Disease
  10.5.2 Sleep and Movement Disease
  10.5.3 Neurodegenerative Disorders
  10.5.4 Psychiatric Disorder
  10.5.5 Gastrointestinal Disease
  10.5.6 Respiratory Disease
  10.5.7 Diabetes
  10.5.8 Others
 10.6 Historic and Forecasted Market Size By End User
  10.6.1 Biopharmaceutical
  10.6.2 Providers
  10.6.3 Payers
 10.7 Historic and Forecast Market Size by Country
  10.7.1 Germany
  10.7.2 U.K.
  10.7.3 France
  10.7.4 Italy
  10.7.5 Russia
  10.7.6 Spain

Chapter 11: Asia-Pacific Digital Biomarkers Market Analysis, Insights and Forecast, 2017-2032
 11.1 Key Market Trends, Growth Factors and Opportunities
 11.2 Impact of Covid-19
 11.3 Key Players
 11.4 Key Market Trends, Growth Factors and Opportunities
 11.4 Historic and Forecasted Market Size By System Component
  11.4.1 Data Collection Tools
  11.4.2 Data Integration Systems
 11.5 Historic and Forecasted Market Size By Therapeutic Area
  11.5.1 Cardiovascular Disease
  11.5.2 Sleep and Movement Disease
  11.5.3 Neurodegenerative Disorders
  11.5.4 Psychiatric Disorder
  11.5.5 Gastrointestinal Disease
  11.5.6 Respiratory Disease
  11.5.7 Diabetes
  11.5.8 Others
 11.6 Historic and Forecasted Market Size By End User
  11.6.1 Biopharmaceutical
  11.6.2 Providers
  11.6.3 Payers
 11.7 Historic and Forecast Market Size by Country
  11.7.1 China
  11.7.2 India
  11.7.3 Japan
  11.7.4 Southeast Asia

Chapter 12: South America Digital Biomarkers Market Analysis, Insights and Forecast,2017-2032
 12.1 Key Market Trends, Growth Factors and Opportunities
 12.2 Impact of Covid-19
 12.3 Key Players
 12.4 Key Market Trends, Growth Factors and Opportunities
 12.4 Historic and Forecasted Market Size By System Component
  12.4.1 Data Collection Tools
  12.4.2 Data Integration Systems
 12.5 Historic and Forecasted Market Size By Therapeutic Area
  12.5.1 Cardiovascular Disease
  12.5.2 Sleep and Movement Disease
  12.5.3 Neurodegenerative Disorders
  12.5.4 Psychiatric Disorder
  12.5.5 Gastrointestinal Disease
  12.5.6 Respiratory Disease
  12.5.7 Diabetes
  12.5.8 Others
 12.6 Historic and Forecasted Market Size By End User
  12.6.1 Biopharmaceutical
  12.6.2 Providers
  12.6.3 Payers
 12.7 Historic and Forecast Market Size by Country
  12.7.1 Brazil
  12.7.2 Argentina

Chapter 13: Middle East & Africa Digital Biomarkers Market Analysis, Insights and Forecast,2017-2032
 13.1 Key Market Trends, Growth Factors and Opportunities
 13.2 Impact of Covid-19
 13.3 Key Players
 13.4 Key Market Trends, Growth Factors and Opportunities
 13.4 Historic and Forecasted Market Size By System Component
  13.4.1 Data Collection Tools
  13.4.2 Data Integration Systems
 13.5 Historic and Forecasted Market Size By Therapeutic Area
  13.5.1 Cardiovascular Disease
  13.5.2 Sleep and Movement Disease
  13.5.3 Neurodegenerative Disorders
  13.5.4 Psychiatric Disorder
  13.5.5 Gastrointestinal Disease
  13.5.6 Respiratory Disease
  13.5.7 Diabetes
  13.5.8 Others
 13.6 Historic and Forecasted Market Size By End User
  13.6.1 Biopharmaceutical
  13.6.2 Providers
  13.6.3 Payers
 13.7 Historic and Forecast Market Size by Country
  13.7.1 Saudi Arabia
  13.7.2 South Africa

Chapter 14 Investment Analysis

Chapter 15 Analyst Viewpoint and Conclusion

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. DIGITAL BIOMARKERS MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. DIGITAL BIOMARKERS MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. DIGITAL BIOMARKERS MARKET COMPETITIVE RIVALRY
TABLE 005. DIGITAL BIOMARKERS MARKET THREAT OF NEW ENTRANTS
TABLE 006. DIGITAL BIOMARKERS MARKET THREAT OF SUBSTITUTES
TABLE 007. DIGITAL BIOMARKERS MARKET BY SYSTEM COMPONENT
TABLE 008. DATA COLLECTION TOOLS MARKET OVERVIEW (2016-2028)
TABLE 009. DATA INTEGRATION SYSTEMS MARKET OVERVIEW (2016-2028)
TABLE 010. DIGITAL BIOMARKERS MARKET BY THERAPEUTIC AREA
TABLE 011. CARDIOVASCULAR DISEASE MARKET OVERVIEW (2016-2028)
TABLE 012. SLEEP AND MOVEMENT DISEASE MARKET OVERVIEW (2016-2028)
TABLE 013. NEURODEGENERATIVE DISORDERS MARKET OVERVIEW (2016-2028)
TABLE 014. PSYCHIATRIC DISORDER MARKET OVERVIEW (2016-2028)
TABLE 015. GASTROINTESTINAL DISEASE MARKET OVERVIEW (2016-2028)
TABLE 016. RESPIRATORY DISEASE MARKET OVERVIEW (2016-2028)
TABLE 017. DIABETES MARKET OVERVIEW (2016-2028)
TABLE 018. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 019. DIGITAL BIOMARKERS MARKET BY END USER
TABLE 020. BIOPHARMACEUTICAL MARKET OVERVIEW (2016-2028)
TABLE 021. PROVIDERS MARKET OVERVIEW (2016-2028)
TABLE 022. PAYERS MARKET OVERVIEW (2016-2028)
TABLE 023. NORTH AMERICA DIGITAL BIOMARKERS MARKET, BY SYSTEM COMPONENT (2016-2028)
TABLE 024. NORTH AMERICA DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA (2016-2028)
TABLE 025. NORTH AMERICA DIGITAL BIOMARKERS MARKET, BY END USER (2016-2028)
TABLE 026. N DIGITAL BIOMARKERS MARKET, BY COUNTRY (2016-2028)
TABLE 027. EUROPE DIGITAL BIOMARKERS MARKET, BY SYSTEM COMPONENT (2016-2028)
TABLE 028. EUROPE DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA (2016-2028)
TABLE 029. EUROPE DIGITAL BIOMARKERS MARKET, BY END USER (2016-2028)
TABLE 030. DIGITAL BIOMARKERS MARKET, BY COUNTRY (2016-2028)
TABLE 031. ASIA PACIFIC DIGITAL BIOMARKERS MARKET, BY SYSTEM COMPONENT (2016-2028)
TABLE 032. ASIA PACIFIC DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA (2016-2028)
TABLE 033. ASIA PACIFIC DIGITAL BIOMARKERS MARKET, BY END USER (2016-2028)
TABLE 034. DIGITAL BIOMARKERS MARKET, BY COUNTRY (2016-2028)
TABLE 035. MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET, BY SYSTEM COMPONENT (2016-2028)
TABLE 036. MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA (2016-2028)
TABLE 037. MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET, BY END USER (2016-2028)
TABLE 038. DIGITAL BIOMARKERS MARKET, BY COUNTRY (2016-2028)
TABLE 039. SOUTH AMERICA DIGITAL BIOMARKERS MARKET, BY SYSTEM COMPONENT (2016-2028)
TABLE 040. SOUTH AMERICA DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA (2016-2028)
TABLE 041. SOUTH AMERICA DIGITAL BIOMARKERS MARKET, BY END USER (2016-2028)
TABLE 042. DIGITAL BIOMARKERS MARKET, BY COUNTRY (2016-2028)
TABLE 043. ALIVECOR INC.: SNAPSHOT
TABLE 044. ALIVECOR INC.: BUSINESS PERFORMANCE
TABLE 045. ALIVECOR INC.: PRODUCT PORTFOLIO
TABLE 046. ALIVECOR INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 046. BAYER AG: SNAPSHOT
TABLE 047. BAYER AG: BUSINESS PERFORMANCE
TABLE 048. BAYER AG: PRODUCT PORTFOLIO
TABLE 049. BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 049. EVIDATION HEALTH INC.: SNAPSHOT
TABLE 050. EVIDATION HEALTH INC.: BUSINESS PERFORMANCE
TABLE 051. EVIDATION HEALTH INC.: PRODUCT PORTFOLIO
TABLE 052. EVIDATION HEALTH INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 052. FITBIT INC.: SNAPSHOT
TABLE 053. FITBIT INC.: BUSINESS PERFORMANCE
TABLE 054. FITBIT INC.: PRODUCT PORTFOLIO
TABLE 055. FITBIT INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 055. HAPPIFY HEALTH: SNAPSHOT
TABLE 056. HAPPIFY HEALTH: BUSINESS PERFORMANCE
TABLE 057. HAPPIFY HEALTH: PRODUCT PORTFOLIO
TABLE 058. HAPPIFY HEALTH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 058. KONINKLIJKE PHILIPS NV: SNAPSHOT
TABLE 059. KONINKLIJKE PHILIPS NV: BUSINESS PERFORMANCE
TABLE 060. KONINKLIJKE PHILIPS NV: PRODUCT PORTFOLIO
TABLE 061. KONINKLIJKE PHILIPS NV: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 061. NEUROTRACK TECHNOLOGIES INC.: SNAPSHOT
TABLE 062. NEUROTRACK TECHNOLOGIES INC.: BUSINESS PERFORMANCE
TABLE 063. NEUROTRACK TECHNOLOGIES INC.: PRODUCT PORTFOLIO
TABLE 064. NEUROTRACK TECHNOLOGIES INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 064. GLAXOSMITHKLINE INC.: SNAPSHOT
TABLE 065. GLAXOSMITHKLINE INC.: BUSINESS PERFORMANCE
TABLE 066. GLAXOSMITHKLINE INC.: PRODUCT PORTFOLIO
TABLE 067. GLAXOSMITHKLINE INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 067. NOVARTIS INTERNATIONAL AG: SNAPSHOT
TABLE 068. NOVARTIS INTERNATIONAL AG: BUSINESS PERFORMANCE
TABLE 069. NOVARTIS INTERNATIONAL AG: PRODUCT PORTFOLIO
TABLE 070. NOVARTIS INTERNATIONAL AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 070. F. HOFFMANN-LA ROCHE LTD.: SNAPSHOT
TABLE 071. F. HOFFMANN-LA ROCHE LTD.: BUSINESS PERFORMANCE
TABLE 072. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 073. F. HOFFMANN-LA ROCHE LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. DIGITAL BIOMARKERS MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. DIGITAL BIOMARKERS MARKET OVERVIEW BY SYSTEM COMPONENT
FIGURE 012. DATA COLLECTION TOOLS MARKET OVERVIEW (2016-2028)
FIGURE 013. DATA INTEGRATION SYSTEMS MARKET OVERVIEW (2016-2028)
FIGURE 014. DIGITAL BIOMARKERS MARKET OVERVIEW BY THERAPEUTIC AREA
FIGURE 015. CARDIOVASCULAR DISEASE MARKET OVERVIEW (2016-2028)
FIGURE 016. SLEEP AND MOVEMENT DISEASE MARKET OVERVIEW (2016-2028)
FIGURE 017. NEURODEGENERATIVE DISORDERS MARKET OVERVIEW (2016-2028)
FIGURE 018. PSYCHIATRIC DISORDER MARKET OVERVIEW (2016-2028)
FIGURE 019. GASTROINTESTINAL DISEASE MARKET OVERVIEW (2016-2028)
FIGURE 020. RESPIRATORY DISEASE MARKET OVERVIEW (2016-2028)
FIGURE 021. DIABETES MARKET OVERVIEW (2016-2028)
FIGURE 022. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 023. DIGITAL BIOMARKERS MARKET OVERVIEW BY END USER
FIGURE 024. BIOPHARMACEUTICAL MARKET OVERVIEW (2016-2028)
FIGURE 025. PROVIDERS MARKET OVERVIEW (2016-2028)
FIGURE 026. PAYERS MARKET OVERVIEW (2016-2028)
FIGURE 027. NORTH AMERICA DIGITAL BIOMARKERS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 028. EUROPE DIGITAL BIOMARKERS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 029. ASIA PACIFIC DIGITAL BIOMARKERS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 030. MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 031. SOUTH AMERICA DIGITAL BIOMARKERS MARKET OVERVIEW BY COUNTRY (2016-2028)